Pegasus Biologics Inc., an Irvine, Calif.-based medical device company focused on the repair of soft-tissue defects in orthopedic, spine and neurosurgery, has raised $10 million in Series B funding. Three Arch Partners and Frazier Healthcare Ventures co-led the deal, and were joined by Life Science Angel Investors. www.pegasusbiologics.com
8 June 2005
